학술논문
Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature.
Document Type
Letter
Author
Source
Subject
*LYMPHOBLASTIC leukemia
*ACUTE leukemia
*ACUTE myeloid leukemia
*LITERATURE reviews
*LEUKOCYTE count
*
*
*
*
Language
ISSN
1042-8194
Abstract
The article presents a case study of a 46-year-old-woman with hyperleukocytosis with asthenia who was enrolled in the GRAALL 2014 clinical trial and received induction therapy with prednisone, daunorubicin, vincristine, cyclophosphamide, and L-asparaginase. Topics discussed include molecular minimal residual disease, an increase in the risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies, and KMT2A gene.